248 related articles for article (PubMed ID: 32346366)
1. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
Piris-Villaespesa M; Alvarez-Twose I
Front Pharmacol; 2020; 11():443. PubMed ID: 32346366
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic efficacy profiles of avapritinib and nintedanib in
Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
[TBL] [Abstract][Full Text] [Related]
4. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
6. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Akin C; Arock M; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.
Akin C
Immunol Allergy Clin North Am; 2023 Nov; 43(4):743-750. PubMed ID: 37758410
[TBL] [Abstract][Full Text] [Related]
10. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
11. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
[TBL] [Abstract][Full Text] [Related]
12. Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
Sandow L; Town A; Heinrich MC
Leuk Res Rep; 2024; 21():100409. PubMed ID: 38273969
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
14. The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
Taylor ML; Dastych J; Sehgal D; Sundstrom M; Nilsson G; Akin C; Mage RG; Metcalfe DD
Blood; 2001 Aug; 98(4):1195-9. PubMed ID: 11493470
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
16. Target Therapies for Systemic Mastocytosis: An Update.
Sciumè M; De Magistris C; Galli N; Ferretti E; Milesi G; De Roberto P; Fabris S; Grifoni FI
Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745657
[TBL] [Abstract][Full Text] [Related]
17. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
18. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in
Schneeweiss-Gleixner M; Filik Y; Stefanzl G; Berger D; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Witzeneder N; Greiner G; Hoermann G; Schiefer AI; Schwaab J; Jawhar M; Reiter A; Sperr WR; Arock M; Valent P; Gleixner KV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804842
[TBL] [Abstract][Full Text] [Related]
19. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]